![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, November 05, 2010 1:03:32 PM
http://www.prnewswire.com/news-releases/geovax-awarded-federal-grant-under-the-qualifying-therapeutic-discovery-project-program-106685598.html
Therapeutic Discovery Project Program
ATLANTA, Nov. 4, 2010 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTC Bulletin Board: GOVX), an Atlanta-based, biopharmaceutical firm dedicated to developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that it has been awarded a grant of $244,500 related to its HIV/AIDS vaccine development activities under the Qualifying Therapeutic Discovery Project ("QTDP") program. GeoVax received the maximum level allowable under the program based on the high number of applicants.
The QTDP program was created by the U.S. Congress as part of the Patient Protection and Affordable Care Act of 2010. It was intended to provide incentive to smaller companies who are focusing on innovative therapeutic discoveries. QTDP grants or tax credits are awarded to companies with fewer than 250 employees for projects related to the treatment or prevention of diseases through the conduct of pre-clinical or clinical studies
The grant was awarded following GeoVax's submission for consideration of its HIV/AIDS vaccine research and development project to the U.S. Secretary of Health and Human Services. Among the determining factors used by the Secretary in allocating funds were those projects that show potential to produce new therapies, address unmet medical needs, and reduce the long-term growth of healthcare costs. Also taken into consideration were the potential for projects to create and sustain high-quality, high-paying U.S. jobs and to advance U.S. competitiveness in the fields of life, biological and medical sciences.
"We are delighted to be the beneficiary of this grant at the maximum level available," said President and CEO Robert T. McNally, PhD. "This grant was allocated following favorable federal review of our project submission, which we believe reflects the potential of our HIV/AIDS vaccine program. These funds and other grant sources continue to support GeoVax's ongoing clinical programs."
Recent GOVX News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 08:15:02 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/30/2024 01:38:39 PM
- GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market • GlobeNewswire Inc. • 08/29/2024 12:59:18 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 08:19:01 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/21/2024 01:22:03 PM
- Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO • GlobeNewswire Inc. • 08/21/2024 01:00:00 PM
- GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market • GlobeNewswire Inc. • 08/20/2024 11:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:12:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:11:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:10:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:10:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:09:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:09:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:08:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:07:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:07:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:06:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 08:06:04 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/13/2024 04:15:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 12:47:49 PM
- GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board • GlobeNewswire Inc. • 08/08/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:05:39 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/06/2024 09:17:09 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/06/2024 09:16:20 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/06/2024 09:15:37 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM